Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.
No abstract available

Publication types

  • Letter

MeSH terms

  • BNT162 Vaccine
  • COVID-19 / epidemiology
  • COVID-19 / prevention & control*
  • COVID-19 / transmission
  • COVID-19 Vaccines / therapeutic use*
  • Humans
  • Infectious Disease Transmission, Patient-to-Professional / prevention & control*
  • Israel / epidemiology
  • Mass Vaccination*
  • Medical Staff, Hospital*
  • Pandemics / prevention & control*
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine